These novel markers can be added to the panel of existing ones like amyloid beta, total Tau and phosphoTau that are currently used for sensitive diagnosis of Alzheimer's disease, either alone or in combination. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.